Abstract Body

Background

The isolated anti-core pattern (antiHBc+, antiHBs-, HBsAg-) is more frequently observed in people living with HIV (PWH). It suggests a past hepatitis B virus (HBV) infection; however, it can also indicate an occult HBV infection, which implicates a risk of viral reactivation. Historically, antiretroviral (ART) regimens containing tenofovir (TXF) have effectively suppressed HBV replication, reducing the risk of reactivation. However, dual HIV therapy regimens now commonly exclude TXF or other drugs with direct anti-HBV activity. The aim of this study was to evaluate the incidence of HBV reactivation in PWH with isolated anti-core pattern who are treated with dual ART regimens lacking TXF: DTG+3TC, DTG+RPV, or CAB+RPV-LA.

Methods

Cross-sectional, single-center study including PWH with a history of isolated anti-core pattern who attended the HIV clinic between April and September 2024. All participants were on dual ART regimens without TXF. HBV serologies (antiHBc, antiHBs, HBsAg) and HBV-DNA levels were measured. Informed consent was obtained from all participants, and the study was approved by the Hospital La Paz Ethics Committee for Medical Research. Results are presented as absolute numbers (%) or medians (interquartile range, IQR).

Results

Of 4219 PWH in our cohort, 9.8% (417) had an isolated anti-HBc pattern, and 32.6% (136) of them were on TXF-free ART regimens. The isolated anti-core pattern was confirmed in 77 of the 123 participants enrolled in the study (56 DTG+3TC; 13 DTG+RPV; 8 CAB+RPV-LA). The median age was 59 years (56-62), and 80% were male. The majority (96.7%) were Caucasian, and 81.6% had a history of cured hepatitis C infection. The median nadir CD4 count was 200 cells/mL (45-301), and the median duration on ART was 24 years (18-27). Among the 21 participants on regimens without HBV-active drugs, no cases of HBV reactivation were observed after a median time on the regimen of 3.6 years (1.1-4.6). The median duration of therapy with DTG+3TC was 3.6 years (2.4-4), and no HBV reactivation was detected in any participant. Only one participant (1/56) on DTG+3TC exhibited a transient HBV-DNA blip (29 IU/mL), which was not confirmed in a follow-up sample.

Conclusions

Our findings suggest that the risk of HBV reactivation in PLHIV with isolated anti-core patterns who are treated with TXF-free dual ART regimens is extremely low after more than 3 years of follow-up. This holds true even for regimens that do not have direct anti-HBV activity, such as DTG+RPV and CAB+RPV-LA.